Sergey Dyshlovoy

Sergey Dyshlovoy is a researcher at the University Medical Center Hamburg-Eppendorf (UKE), affiliated with the II. Medical Clinic and Polyclinic. His academic credentials include a PD Dr. rer. nat., DSc in Biochemistry, PhD in Chemistry, and a Dipl.-Chem. degree.

His research focuses on prostate cancer, particularly oligometastatic hormone-sensitive prostate cancer and aggressive variant neuroendocrine prostate cancer, with an emphasis on targeted therapies like TROP2 inhibition and circulating tumor cell analysis. He also explores anticancer compounds (e.g., tetracyclic dispiro ozonides, fascaplysins) and marine-derived antimicrobials (e.g., Stonikacidin A). Additional work includes applications of nanopore sequencing in precision oncology and lectin-based antiproliferative agents for lymphoma.

He collaborates with interdisciplinary teams at UKE’s research centers like the University Cancer Center Hamburg (UCCH) and engages in clinical research projects related to cancer therapy, drug development, and molecular diagnostics.